WuXi Biologics Brand Guidelines: A 2010 WuXi AppTec Unit, a 2017 Listing & BIOSECURE

A biologics unit of a Shanghai chemistry firm.

WuXi Biologics grew out of WuXi AppTec, the contract research company that the chemist Ge Li founded in Shanghai in December 2000 as WuXi PharmaTech, Wikipedia says. Its article on WuXi Biologics dates the biologics business’s roots to 2010, when it began as a division of WuXi AppTec building the capabilities and plants needed for biologics discovery, development and manufacturing; the WuXi AppTec article places the start of the biologics operation, in Shanghai and in Wuxi city, in 2011, and a GMP drug-substance plant in Wuxi in 2012.

The division was spun off from its parent and listed on the Hong Kong Stock Exchange in June 2017, Wikipedia says. In August 2020 it was selected as a component of the Hang Seng Index. The company describes itself as a CRDMO — a contract research, development and manufacturing organisation — and states its vision in five words: “Every biologic can be made.”

The name follows the parent’s. The capitalised X in WuXi is shared across the group, and Wikipedia gives the pronunciation as “Wu-shee.” In November 2023 WuXi Biologics’ own subsidiary WuXi XDC, which works on antibody-drug conjugates, listed on the main board of the Hong Kong exchange, the company says.

Bioreactors from Wuxi to Worcester.

Much of the work is done in China. Wikipedia lists two sites in Wuxi city, where the Mashan site holds several numbered manufacturing facilities and a second site is dedicated to antibody-drug conjugates, alongside sites in Shanghai, Hangzhou, Suzhou, Chengdu and Shijiazhuang. In March 2021 the company agreed to take over a new biotechnology centre in Hangzhou built by Pfizer China, and to acquire a controlling stake in CMAB Biopharma in Suzhou, Wikipedia says. The company says it completed the first commercial process-validation run on a 15,000-litre single-use bioreactor line in Hangzhou in April 2025.

Abroad, the company built a drug-substance plant in Dundalk, Ireland, announced in 2018 with support from IDA Ireland and designed around single-use bioreactors, Wikipedia says; WuXi Biologics says the Irish facility completed its first 16,000-litre run in January 2024 and received its first EMA approval for commercial manufacturing in August 2025. In Germany it took over a fill site in Leverkusen from Bayer in 2020 and agreed later that year to buy a Bayer drug-substance site in Wuppertal.

In the United States, Wikipedia records a plant at The Reactory in Worcester, Massachusetts, announced in May 2020, a clinical manufacturing facility in Cranbury, New Jersey, and a process-development lab in King of Prussia, Pennsylvania, which the company said in 2024 would close. The company dates the GMP release of Cranbury, its first North American biomanufacturing facility, to August 2022. A Singapore centre broke ground in March 2024, it says.

The services run from antibody discovery and cell-line development to clinical and commercial drug substance, drug product and pre-filled syringes, according to the company’s site. It lists recognition including the ISPE Facility of the Year Award in 2023 and CDMO Leadership Awards in several years.

The range has widened by type of molecule as well as by place. The company dates its first commercial drug-product facility for pre-filled syringes to June 2022, and its move into development and manufacturing of microbial-derived products, made with bacterial and yeast expression systems for plasmid DNA and recombinant proteins, to July 2022. In June 2025 it began building a microbial site for commercial production in Chengdu, and its Singapore project is planned as a 13.5-hectare centre combining research, development and manufacturing, the company says.

How drug-manufacturing partners present themselves.

Contract development and manufacturing organisations, or CDMOs, make medicines for other companies. A drug developer may hand them a cell line, a molecule or a finished formula, and the partner develops the process, makes the drug substance, fills it into vials, syringes or capsules and packs it for trials or for sale. Most of that work happens out of public view, under the customer’s name rather than the maker’s, so the manufacturer’s own brand speaks mainly to other businesses.

The imagery of the trade is fairly consistent. Websites and brochures tend to show tall stainless-steel bioreactors and rows of single-use bags in bright, white production suites; operators in full gowns, hoods and gloves working in cleanrooms; and filling lines carrying glass vials. Aerial photographs of large new plants, often shown under construction or on opening day, stand in for scale, and site maps of a global network do the same job for reach.

Much of the brand work happens at trade events. CPHI, the pharmaceutical trade fair, and the BIO International Convention in the United States are where these companies take stands, announce deals and, at times, unveil new identities: Pharma Manufacturing reported that Catalent introduced its new corporate brand at CPHI Frankfurt in 2025.

This guide sets out what can be checked about each company — where it began, who owns it now, which sites and services it describes, and what has been reported about it — and separates documented facts from what the companies say about themselves. The colours and typefaces used here are our own interpretation, not official brand assets.

Named in a US bill, absent from the final law.

Since 2024 the company’s public story has been shaped by US legislation. In January 2024 WuXi Biologics’ share price fell after a bill was introduced in Congress to block federal contracts with the company on national-security grounds, Wikipedia says; the concerns rested on allegations of ties to China’s military, which the company denied. In February 2024 members of the House Select Committee on the Chinese Communist Party joined two senators in urging a review of WuXi AppTec and WuXi Biologics for possible sanctions.

In January 2025 WuXi Biologics agreed to sell its vaccine plant in Dundalk to MSD, which had been its only customer there under a 20-year supply contract, with completion then expected in the first half of 2025, BreakingNews.ie reported, citing Reuters. The BIOSECURE Act was signed into law on 18 December 2025 as part of the National Defense Authorization Act for fiscal 2026. Earlier drafts had named five companies, including WuXi AppTec and WuXi Biologics, but the enacted text names none; instead the Office of Management and Budget is to publish a list of biotechnology companies of concern by December 2026, the law firm Arnold & Porter wrote that month. At enactment WuXi Biologics was not on the Pentagon’s “1260H” list of Chinese military companies, the FDA Law Blog noted in June 2026, when the list’s update added WuXi AppTec.

For a design guide, WuXi Biologics shows how a contract partner signals reach through a dense network of numbered facilities, a coined category label in CRDMO and a single-line vision, while carrying a group name with a distinctive capital X. Compare Samsung Biologics, another Asian biologics manufacturer built on scale, and Lonza. For this guide we use a deep teal, a lab green and a pale jade with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep WuXi Biologics’s identity on hand — save it to a board in the Made Good inspiration library.